Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AR Antivirals for treatment of HIV infections, combinations
J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
D10755 Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Combinations
Cobicistat/ Elvitegravir/ Emtricitabine/ Tenofovir Alafenamide
D10755 Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D10755 Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
D10755 Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D10755 Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HIV integrase inhibitor
D10755 Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10755
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10755
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10755
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10755